Project Grant R01HL170245

Award Date 7/1/24
Completion Date 6/30/29
Dollars Obligated $750K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45221, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $739,466 to The University of Texas Southwestern Medical Center to develop a comprehensive PET attenuation correction scheme for cardiac PET/MR imaging. The goal is to enable precise PET quantification and improve the diagnostic performance of combined PET/MR exams for evaluating cardiac sarcoidosis and other heart diseases. The award...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $616,033 to the University of California, Davis to develop and validate a PET-enabled dual-energy CT (DECT) imaging method. The goal is to create a technique that can derive a high-energy gamma-ray CT (GCT) image from standard PET/CT emission data, and combine it with...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,614,450.00 to The Regents of the University of California, San Francisco to develop and translate hyperpolarized 13C-pyruvate MRI technology for evaluating metabolic remodeling in heart disease. The key goals are to: Develop hyperpolarized 13C-pyruvate MRI methods to assess metabolic flexibility and glycolysis-glucose oxidation coupling under different...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $666,670 to The Trustees of the University of Pennsylvania to develop innovative scan protocols that combine long axial field-of-view PET and spectral CT imaging for improved quantification in oncology. The goal is to create methods and protocols to obtain high-quality dynamic information from both PET and CT modalities, and to use dynamic spectral CT for PET...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $129,612 to Case Western Reserve University (CWRU) to develop new AI-based methods for evaluating high-risk coronary atherosclerotic plaque using non-invasive coronary CT angiography (CCTA) imaging. The research aims to compare CCTA image features to high-resolution intravascular optical coherence tomography (IVOCT) imaging, considered...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), will support the development and optimization of a modular time-of-flight (TOF) positron emission tomography (PET) prototype scanner. The goal is to create a flexible PET system with an extended axial field of view over 1 meter, which can enable faster and more cost-effective...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This $604,115 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a longitudinal observational study by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop non-invasive advanced imaging technologies to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $656,751 to Third Coast Dynamics, Inc. to develop an artificial intelligence-based platform called "TCDFLOW" that can derive 4D hemodynamic data from routine clinical anatomic images. This will address limitations of current 4D flow MRI techniques, which require specialized equipment and expertise, by enabling the...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the CFDA program "Discovery and Applied Research for Technological Innovations to Improve Human Health" (93.286), will fund the development of a novel real-time interactive Positron Emission Tomography (PET) and Ultrasound (US) imaging technology. The goal is to enable interactive PET and US scanning with real-time visualization of molecular contrast fused with US images to...

NOVEL METHODOLOGIES TO IMPROVE CORONARY ARTERY DISEASE DIAGNOSTICS WITH DYNAMIC PET - PROJECT SUMMARY/ABSTRACT DYNAMIC PET MYOCARDIAL PERFUSION IMAGING IS EMERGING AS A NEW MODALITY TO QUANTITATIVELY MEASURE MYOCARDIAL BLOOD FLOW AND FLOW RESERVE AND HAS IMPROVED THE DIAGNOSTIC AND PROGNOSTIC ASSESSMENTS OF CORONARY ARTERY DISEASE (CAD) COMPARED WITH OTHER IMAGING TECHNIQUES. HOWEVER, FLOW QUANTIFICATION BY THE STANDARD THREE-DIMENSIONAL (3D) APPROACH FACES A SUBSTANTIAL NOISE CHALLENGE DUE TO FURTHER DIVIDING THE NOISY TOMOGRAPHIC DATA INTO SHORTER FRAMES FOR IMAGE RECONSTRUCTION BEFORE TIME ACTIVITY CURVES ARE EXTRACTED FOR KINETIC ANALYSIS. FOUR-DIMENSIONAL (4D) PARAMETRIC IMAGE RECONSTRUCTION INCORPORATES KINETIC MODELING INTO DIRECTLY ESTIMATING PARAMETRIC IMAGES FROM ENTIRE RAW DATA. IT HAS STATISTICAL ADVANTAGES OVER THE INDIRECT 3D METHOD BY ACCURATELY MODELING NOISE IN THE PROJECTION SPACE. HOWEVER, DIRECT PARAMETRIC IMAGE ESTIMATION STILL SUFFERS FROM THE INHERENT ILL-POSEDNESS OF THE RECONSTRUCTION PROBLEM, TO WHICH SPATIAL REGULARIZATION EXTENSIVELY DEVELOPED IN STATIC PET IMAGING HAS RARELY BEEN EXPLORED. FURTHERMORE, 4D DIRECT RECONSTRUCTION HAS TYPICALLY BEEN INVESTIGATED AT THE CONCEPT IMPLEMENTATION STAGE WITH VERY LIMITED ANIMAL OR PATIENT STUDY VALIDATION. IN THIS PROJECT, WE PROPOSE TO DEVELOP NOVEL DATA-DRIVEN MOTION CORRECTED DIRECT 4D PARAMETRIC IMAGE RECONSTRUCTION TECHNIQUES INTEGRATING UNSUPERVISED DEEP LEARNING-BASED REGULARIZATION TO REDUCE NOISE WHILE MAINTAINING QUANTITATIVE ACCURACY IN DYNAMIC 82RB PET MP IMAGING. WE WILL DEVELOP AND VALIDATE THE TECHNIQUES IN TERMS OF GLOBAL AND REGIONAL NOISE REDUCTION USING LARGE ANIMAL MODELS OF ISCHEMIA AND MYOCARDIAL INFARCTION (MI), PATIENTS WITH SUSPECTED ISCHEMIC HEART DISEASE (IHD), AND PATIENTS FOLLOWING MI REFERRED FOR ASSESSMENT OF VIABILITY. THE PERFORMANCE OF THE PROPOSED METHOD WILL BE COMPARED WITH THE STANDARD INDIRECT 3D APPROACH AND WITH NON-REGULARIZED AND OTHER REGULARIZED 4D METHODS. WE HYPOTHESIZE THAT THE PROPOSED TECHNIQUES WILL SIGNIFICANTLY REDUCE MEASUREMENT UNCERTAINTY OF 82RB KINETICS, LEADING TO IMPROVED TEST-RETEST REPEATABILITY, DIAGNOSTIC ACCURACY IN EVALUATING IHD, AND RELIABILITY IN ACCESSING MYOCARDIAL VIABILITY WITH REST 82RB MP IMAGING ALONE. THE PROPOSED LEARNING REGULARIZED DIRECT 4D PARAMETRIC RECONSTRUCTION WILL BE THE FIRST ATTEMPT TO INTEGRATE DEEP LEARNING-BASED DENOISING TO RESOLVE THE LOW SIGNAL TO NOISE RATIO CHALLENGE IN DYNAMIC PET IMAGING. THE ADVANCEMENTS BROUGHT BY THIS PROJECT WILL ENABLE DYNAMIC 82RB IMAGING FOR 1) DETECTION AND RISK STRATIFICATION OF PATIENTS WITH OBSTRUCTIVE CAD AND ISCHEMIA WITH NON-OBSTRUCTIVE CORONARY ARTERIES (INOCA), AND 2) IDENTIFICATION OF MYOCARDIAL VIABILITY IN PATIENTS WITH IHD REFERRED FOR POTENTIAL REVASCULARIZATION. IN PATIENTS REFERRED FOR EVALUATION OF MYOCARDIAL VIABILITY, THE PROPOSED METHOD WILL DISCRIMINATE HIBERNATING MYOCARDIUM FROM SCAR WITH A SINGLE REST 82RB PET SCAN. THE PROPOSED EFFORTS WILL REVOLUTIONIZE THE EVALUATION AND MANAGEMENT OF PATIENTS WITH SUSPECTED OR KNOWN CAD OR THOSE BEING CONSIDERED FOR CORONARY REVASCULARIZATION TO INCREASE CLINICAL EFFICIENCY AND REDUCE HEALTHCARE COST.

Posted 6/10/24